(Q43778450)

26 November 2017

title

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients (English)

1 reference

26 November 2017

1 reference

Charpentier G

1

1 reference

26 November 2017

Fleury F

2

1 reference

26 November 2017

Kabir M

3

1 reference

26 November 2017

Vaur L

4

1 reference

26 November 2017

Halimi S

5

1 reference

26 November 2017

publication date

1 October 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

18

1 reference

26 November 2017

issue

10

1 reference

26 November 2017

page(s)

828-834

1 reference

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Insulin and atheroma. 20-yr perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Insulin and Cardiovascular Disease: Paris Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Oral antidiabetic agents. A guide to selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

An overview of metformin in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00582.X

10.1046/J.1464-5491.2001.00582.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference